Borgeson Blake has made headlines with its recent stock transaction involving the sale of 40,000 shares of Recursion Pharmaceuticals, Inc. This significant move, reported on November 4, 2026, is noteworthy as it illustrates the ongoing activity within the life sciences sector.

Company Overview

Borgeson Blake is a reporting entity with a Central Index Key (CIK) of 0001856094. The company is associated with Recursion Pharmaceuticals, which operates under the SIC classification of Biological Products (No Diagnostic Substances) [2836]. Recursion is incorporated in Delaware and is based in Salt Lake City, Utah.

Details from the Filing

The recent SEC filing, accession number 0001601830-26-000150, details that Borgeson Blake sold 40,000 shares of Class A Common Stock of Recursion Pharmaceuticals on November 3, 2026. The transaction was executed at an average price of $3.88 per share, with the total number of shares owned following the transaction rising to 6,068,287. This sale was conducted under a Rule 10b5-1 trading plan that Borgeson adopted on August 31, 2025.

Impact of the Transaction

This transaction may have various implications for Borgeson Blake and Recursion Pharmaceuticals. It highlights Borgeson’s active management of its investment in Recursion, which could affect shareholder perceptions and market dynamics. Stakeholders in the life sciences sector may also take note of this activity as it reflects broader trends in the industry.

What’s Next?

The filing does not say what happens next.